KT - KT Corporation invests $5M in NeuroSigma

KT Corporation (NYSE:KT) has made a $5M equity investment in NeuroSigma. NeuroSigma is the developer of the Monarch eTNS System, which uses non-invasive external trigeminal nerve stimulation to treat neurological and neuropsychiatric indications, including ADHD, depression, and epilepsy. The therapy is the first device-based, non-drug therapy approved by the FDA to treat pediatric ADHD. Investment proceeds will be used to fund the pilot commercialization of the Monarch eTNS System in the U.S., development of the next generation of the eTNS device, additional clinical studies, and application for expanded regulatory approvals in the U.S. and other territories. The transaction follows the June 2021 announcement of a strategic digital health partnership between NeuroSigma and KT. Through this existing partnership, the two companies will work together to commercialize and establish manufacturing of products in Korea as part of the KT digital healthcare platform

For further details see:

KT Corporation invests $5M in NeuroSigma